Dificid Taps into CMS' New Technology Payment Program
WASHINGTON – Optimer Pharmaceuticals Inc.'s Dificid hit the market a few years too soon to take advantage of the exclusivity offered for new antibiotics under the FDA Safety and Innovation Act (FDASIA), but the Clostridium difficile-fighting drug is getting a regulatory hand up from another agency.
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter